title: Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis.
abstract: Eighteen patients affected by laparoscopically confirmed endometriosis were randomly assigned to three different schedules of treatment with gonadotropin-releasing hormone agonist (GnRH-a) (goserelin depot formulation 3.6 mg) every 28 days for 6 months. Six women received the first implant in early follicular phase, 4 in late luteal phase and 8 in 3rd and 17th day from onset of menses. Pretreatment and posttreatment laparoscopic score, performed according to the American Fertility Society scoring system, were compared; a significant reduction in the extent of disease was observed in each group investigated (A and C: p < 0.01; B: p < 0.05). In each treatment group after the second GnRH-a implant the mean levels of estrone-3-glucuronide (E1-3G), daily measured in early morning urine specimens during the control cycle and the first three months of therapy, were suppressed to menopausal women range. In group B during the 2nd and 3rd month of therapy, the urinary mean levels of E1-3G were significantly lower than in group A and C. In conclusion the different goserelin depot administration schedules gave similar laparoscopic improvement, in spite of the first GnRH-a administration in luteal phase allowed a more marked estrogenic suppression.
authors.affiliation: Unità di Endocrinologia, University of Florence, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Magini
authors.forename: S
authors.initials: S
authors.lastname: Pellegrini
authors.forename: K
authors.initials: K
authors.lastname: Tavella
authors.forename: G
authors.initials: G
authors.lastname: Forti
authors.forename: G B
authors.initials: GB
authors.lastname: Massi
authors.forename: M
authors.initials: M
authors.lastname: Serio
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000188:drug therapy* / Q000652:urine; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004970:Estrone / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D005498:Follicular Phase; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010535:Laparoscopy; D008183:Luteal Phase; D007986:Luteinizing Hormone / Q000652:urine; D010050:Ovarian Function Tests; D011276:Pregnanediol / Q000031:analogs & derivatives / Q000652:urine
chemical_list: D003692:Delayed-Action Preparations; D004965:Estrogen Antagonists; D017273:Goserelin; C022270:pregnanediol-3 alpha-glucuronide; C015856:estrone-3-glucuronide; D004970:Estrone; D007986:Luteinizing Hormone; D011276:Pregnanediol